WS #15163
Holding: newest synthesis is 4d 16h old
Eli Lilly reported positive Phase 3 data for its retatrutide obesity drug, reinforcing its leadership in the weight-loss market. In oncology, Citi initiated new Buy ratings on Nuvation and Jazz, while JP Morgan raised its target on Annexon, indicating strong analyst conviction in the sector's near-term growth prospects despite broader market volatility.
Pharma and Biotech Catalysts
Eli Lilly reported positive Phase 3 data for its retatrutide obesity drug, reinforcing its leadership in the weight-loss market. In oncology, Citi initiated new Buy ratings on Nuvation and Jazz, while JP Morgan raised its target on Annexon, indicating strong analyst conviction in the sector's near-term growth prospects despite broader market volatility.